EnClear Therapies is a Newburyport-based company dedicated to improving and extending the lives of patients suffering from central nervous system (CNS) disorders, such as neurodegenerative diseases and CNS malignancies. They utilize their proprietary EnTrega CSF Platform to provide precision dosing of CNS-based therapeutics, reducing the risk of severe side effects and peripheral toxicity.
With a two-fold strategy, EnClear Therapies aims to address the $1.2 billion market need in neuro-oncology and expand their portfolio through partnerships into next-generation personalized medicine for neurodegenerative, lysosomal storage, and autoimmune diseases.
Generated from the website